Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

McGill University

$27,000.00

Evaluating Novel Therapeutic Approaches for NRAS Mutant Melanoma

FY 2025-26

Summary
Metastatic melanoma is a fatal cancer. Around 20-30% of cutaneous melanomas are driven by an NRAS gene mutation. Immune Checkpoint Inhibitors (ICI) have improved survival rates for melanoma but NRAS mutant melanoma is associated with resistance. NRAS-mutant tumors may resist ICI through inhibiting anti-cancer immune signals. Our lab has investigated immune-related effectors associated with NRAS and identified LNK (SH2B3), an adaptor protein. LNK is known to inhibit interferon-gamma signalling, which T cells use to promote cancer-cell death. Therefore, LNK could be allowing NRAS mutant melanoma to survive immune attack. Our project uses the breakthrough pan-RAS inhibitor, RMC-7977, to investigate the relationship between NRAS-inhibition and LNK. We hypothesize that RMC-797 will suppress NRAS and LNK expression and restoring tumor sensitivity to interferon gamma. We will focus on three goals: Evaluate RMC-7977 in melanoma models: We will confirm how RMC-7977 blocks cancer growth signals and suppresses LNK across different mutational subtypes of melanoma, ensuring its is specific to NRAS mutations. Evaluate the role of LNK: Using genetically engineered melanoma cells where LNK is either knocked out or overexpressed, we will determine if LNK is a key factor that causes tumors to limit interferon gamma signalling and as well as the efficacy of RMC-7977. Evaluate New Strategies in Vivo: We will test whether LNK knockout makes the tumors significantly more sensitive to RMC-7977 in animal models. This project defines LNK as a new target for NRAS mutant melanoma, potentially allowing us to re-sensitize tumors to immune signaling and enhancing the therapeutic effect of RMC-7977. This work could provide a much-needed precision therapy for patients with this aggressive cancer.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572980
Name
Vrkoc Meghan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating Novel Therapeutic Approaches for NRAS Mutant Melanoma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Akt Signalling; Antitumor Immunity; Cytokine Signalling; Ifn / Jak-Stat Pathway; Immune Checkpoint Inhibitor (Ici) Resistance; Lnk (Sh2b3); Mapk Signalling; Nras-Mutant Melanoma; Rmc-7977; Tumor Immune Microenvironment (Time)
Abstract
Metastatic melanoma is a fatal cancer. Around 20-30% of cutaneous melanomas are driven by an NRAS gene mutation. Immune Checkpoint Inhibitors (ICI) have improved survival rates for melanoma but NRAS mutant melanoma is associated with resistance. NRAS-mutant tumors may resist ICI through inhibiting anti-cancer immune signals. Our lab has investigated immune-related effectors associated with NRAS and identified LNK (SH2B3), an adaptor protein. LNK is known to inhibit interferon-gamma signalling, which T cells use to promote cancer-cell death. Therefore, LNK could be allowing NRAS mutant melanoma to survive immune attack. Our project uses the breakthrough pan-RAS inhibitor, RMC-7977, to investigate the relationship between NRAS-inhibition and LNK. We hypothesize that RMC-797 will suppress NRAS and LNK expression and restoring tumor sensitivity to interferon gamma. We will focus on three goals: Evaluate RMC-7977 in melanoma models: We will confirm how RMC-7977 blocks cancer growth signals and suppresses LNK across different mutational subtypes of melanoma, ensuring its is specific to NRAS mutations. Evaluate the role of LNK: Using genetically engineered melanoma cells where LNK is either knocked out or overexpressed, we will determine if LNK is a key factor that causes tumors to limit interferon gamma signalling and as well as the efficacy of RMC-7977. Evaluate New Strategies in Vivo: We will test whether LNK knockout makes the tumors significantly more sensitive to RMC-7977 in animal models. This project defines LNK as a new target for NRAS mutant melanoma, potentially allowing us to re-sensitize tumors to immune signaling and enhancing the therapeutic effect of RMC-7977. This work could provide a much-needed precision therapy for patients with this aggressive cancer.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vrkoc, Meghan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~